Current Trials

These are some of the clinical trials that GLCC are currently working on. Together with our clients, we strive to deliver the most efficient and cost-effective services.

Diabetes

  • TECOS

    • Diabetes
    • PHASE III
    • 14,000 participants
    • 12 sites in New Zealand
    • 36 participating countries

    TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin

    A randomised, placebo controlled clinical Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with Type 2 Diabetes Mellitus and inadequate glycemic control on mono-or dual combination oral antihyperlycemic therapy (TECOS)

    This is a multinational, placebo-controlled, double-blind, randomised, parallel-group pragmatic clinical trial. The purpose of this study is to assess the impact of sitagliptin therapy upon cardiovascular (CV) outcomes in a large population from a diverse group of countries and practice environments.

    More about the TECOS study

Trial Types

Our People

At GLCC we strongly believe people are our biggest asset. Together with support from national and international academia, research registrars and fellows, we are dedicated to achieving the highest possible standard in clinical research.

Benefits of conducting trials in New Zealand

  • Well established clinical trial infrastructure
  • Excellent recruitment and retention rates
  • High standard of medical practice
  • High standard of clinical trial data
  • Adherence to ICH/GCP and FDA regulations
  • Regulatory framework based on European and American systems

Learn more about conducting clinical trials in New Zealand